AMSTERDAM--(BUSINESS WIRE)--PresbiBio LLC, a wholly owned subsidiary of Presbia Holdings, a medical device company and leader in near vision restoration, announced today that it has received conditional approval from the United States Food and Drug Administration (FDA) of its Investigational Device Exemption (IDE) application to commence a Phase II trial of the Presbia Flexivue Microlens™, a corneal inlay.
Help employers find you! Check out all the jobs and post your resume.
